Key points from article :
OneSkin, a biotech skincare brand, has secured $20 million in Series A funding to accelerate its mission of developing peptide-based solutions for healthier, younger-looking skin. Founded by a team of Brazilian scientists, OneSkin aims to address skin aging at a molecular level by targeting senescent cells, a key factor in the aging process. This influx of capital will enable OneSkin to expand its research and development efforts, launch new products, and expand its market reach.
Carolina Oliveira, Co-Founder and CEO of OneSkin, highlights the company's focus on aesthetic and functional benefits sets it apart in the skincare industry. By combining cutting-edge science with innovative formulations, OneSkin aims to deliver products that not only improve the appearance of skin but also promote overall skin health.
"This investment will allow us to deepen our commitment to be the best in class in delivering efficacious peptides to modulate aging at the cellular level, ensuring that our science-backed solutions deliver measurable results in promoting healthier skin," said Alessandra Zonari, Co-Founder and CSO of OneSkin.
OneSkin's unique approach, combined with its strong investor backing, positions the brand as a leader in the future of skincare. As the demand for science-backed beauty solutions continues to grow, OneSkin is well-positioned to capitalize on this trend and redefine the standards of skin care.
